Quinn Opportunity Partners LLC Sage Therapeutics, Inc. Transaction History
Quinn Opportunity Partners LLC
- $1.08 Billion
- Q2 2025
A detailed history of Quinn Opportunity Partners LLC transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Quinn Opportunity Partners LLC holds 24,888 shares of SAGE stock, worth $216,027. This represents 0.02% of its overall portfolio holdings.
Number of Shares
24,888Holding current value
$216,027% of portfolio
0.02%Shares
1 transactions
Others Institutions Holding SAGE
# of Institutions
223Shares Held
51.4MCall Options Held
220KPut Options Held
425K-
Black Rock Inc. New York, NY5.22MShares$45.3 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.08MShares$44.1 Million0.0% of portfolio
-
Madison Avenue Partners, LP New York, NY4.48MShares$38.9 Million4.6% of portfolio
-
Tig Advisors, LLC New York, NY2.73MShares$23.7 Million1.36% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY2.09MShares$18.1 Million0.02% of portfolio
About Sage Therapeutics, Inc.
- Ticker SAGE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,422,300
- Market Cap $516M
- Description
- Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...